Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib, Double-Masked, Multiple-Ascending Dose Trial to Evaluate an Eye Drop Formulation of AKB-9778 for Treatment of Primary Open Angle Glaucoma (POAG)

Next Previous
Trial Profile

A Phase Ib, Double-Masked, Multiple-Ascending Dose Trial to Evaluate an Eye Drop Formulation of AKB-9778 for Treatment of Primary Open Angle Glaucoma (POAG)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Razuprotafib (Primary) ; Prostaglandins
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Adverse reactions
  • Sponsors Aerpio Pharmaceuticals

Most Recent Events

  • 07 Feb 2020 According to an Aerpio Pharmaceuticals media release, data from the fifth cohort of subjects were presented at the Glaucoma 360 New Horizons Forum 2020.
  • 08 Jan 2020 Results from the additional fifth cohort published in the Aerpio Pharmaceuticals media release.
  • 08 Jan 2020 According to an Aerpio Pharmaceuticals media release, based on favorable tolerability and pharmacodynamic findings in ocular normotensive subjects (results declared on October 10, 2019), Aerpio elected to recruit a fifth cohort (n=43) of subjects with ocular hypertension /primary open angle glaucoma on standard of care prostaglandin therapy to assess the safety, tolerability and pilot efficacy of once-daily AKB-9778 (40 mg/ml) as an adjunctive therapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top